{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:43:41Z","timestamp":1791413021686,"version":"4.3.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01827-6","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:25:00Z","timestamp":1782368700000},"page":"3847-3860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Borkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassandra","family":"Schaible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarif","family":"Jabbar Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramkumar","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Puelles","family":"Fern\u00e1ndez de Troc\u00f3niz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"6","key":"1827_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.183.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1827_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.14722","volume":"46","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Choi J, Sutaria N, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277\u201384. https:\/\/doi.org\/10.1111\/ced.14722.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1827_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","volume":"86","author":"KA Whang","year":"2022","unstructured":"Whang KA, Le TK, Khanna R, et al. Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol. 2022;86(3):573\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.036.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1827_CR4","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","volume":"141","author":"S Wongvibulsin","year":"2021","unstructured":"Wongvibulsin S, Sutaria N, Williams KA, et al. A nationwide study of prurigo nodularis: disease burden and healthcare utilization in the United States. J Invest Dermatol. 2021;141(10):2530\u20133. https:\/\/doi.org\/10.1016\/j.jid.2021.02.756.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1827_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase\u00a03 trials. Nat Med. 2023;29(5):1180\u201390. https:\/\/doi.org\/10.1038\/s41591-023-02320-9.","journal-title":"Nat Med"},{"issue":"17","key":"1827_CR6","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase\u00a03 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2301333.","journal-title":"N Engl J Med"},{"issue":"8","key":"1827_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1908316.","journal-title":"N Engl J Med"},{"key":"1827_CR8","unstructured":"Puelles J, de la Cruz M, Murphy R, Devlen J, Gabriel S. Qualitative equivalence of the worst itch and peak pruritus numerical rating scales in prurigo nodularis [poster]. 35th Congress of the European Academy of Dermatology and Venereology; September 29\u2013October 2, 2021."},{"key":"1827_CR9","unstructured":"Cochrane Collaboration. Risk of bias 2 (RoB 2) tool. Updated Nov 2021. https:\/\/methods.cochrane.org\/risk-bias-20-tool. Accessed Jan 20, 2026."},{"key":"1827_CR10","unstructured":"National Institute for Health and Care Excellence. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. Technology appraisal guidance TA814. 2022 (updated Aug 3, 2022). https:\/\/www.nice.org.uk\/guidance\/ta814. Accessed Jan 20, 2026."},{"key":"1827_CR11","unstructured":"National Institute for Health and Care Excellence. Baricitinib for treating moderate to severe atopic dermatitis. Technology appraisal guidance TA681. 2021 (updated Mar 3, 2021). https:\/\/www.nice.org.uk\/guidance\/ta681. Accessed Jan 20, 2026."},{"key":"1827_CR12","unstructured":"National Institute for Health and Care Excellence. Dupilumab for treating moderate to severe atopic dermatitis. Technology appraisal guidance TA534. 2018 (updated Aug 1, 2018). https:\/\/www.nice.org.uk\/guidance\/ta534. Accessed Jan 20, 2026."},{"key":"1827_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4796","author":"S St\u00e4nder","year":"2024","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase\u00a03 trial. JAMA Dermatol. 2024. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4796.","journal-title":"JAMA Dermatol"},{"key":"1827_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdin.2024.03.025","volume":"16","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G, Kim BS, Kwatra SG, et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from 2 phase\u00a03 trials (LIBERTY-PN PRIME and PRIME2). JAAD Int. 2024;16:163\u201374. https:\/\/doi.org\/10.1016\/j.jdin.2024.03.025.","journal-title":"JAAD Int"},{"issue":"2","key":"1827_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","volume":"161","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase\u00a03 trial. JAMA Dermatol. 2025;161(2):147\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4796.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1827_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jid.2023.12.003","volume":"144","author":"XY Wang","year":"2024","unstructured":"Wang XY, Jia QN, Wu MY, Liu MJ, Mi X, Li J. Comparing the efficacy of updated treatment choices for prurigo nodularis: a network meta-analysis. J Invest Dermatol. 2024;144(6):1409-12 e7. https:\/\/doi.org\/10.1016\/j.jid.2023.12.003.","journal-title":"J Invest Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01827-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:01Z","timestamp":1787243401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01827-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1827"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01827-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gil Yosipovitch is a consultant and a board member of Abbvie, Arcutis, Almiral, Amgen, Celldex, Escient Health, Eli Lilly, Galderma, GSK, Kiniksa, LEO Pharma, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, Vifor, and Pfizer. Gil Yosipovitch is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Katarzyna Borkowska, James Frampton, Kassandra Schaible, Marissa Betts, and Binod Neupane are employees of PPD Evidera, the clinical research business of Thermo Fisher Scientific, which received funding from Galderma in connection with the development of this manuscript and research. Katrin Jack, Zarif Jabbar Lopez, Christophe Piketty, Ramkumar Subramanian, and Jorge Puelles Fern\u00e1ndez de Troc\u00f3niz are employees of Galderma and hold company stock.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}